{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-008804","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2022-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.969668+00:00","generated_at":"2026-06-26T08:25:46.420914+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cardiff Oncology announces updated Phase 2 mCRPC data and preclinical ovarian cancer data for onvansertib","bullets":["Arm C (12 mg/m2 onvansertib days 1-14) achieved 75% radiographic stable disease at 12 weeks vs 53% in Arm A.","Median progression-free survival increased from 4.1 months in Arm A to 13.2 months to-date in Arm C.","Combination of onvansertib with olaparib overcame PARP inhibitor resistance in BRCA1-mutant and wildtype PDX ovarian cancer models.","Mutations in PTEN and MTOR were positively associated with treatment response in mCRPC trial patients.","Disease control by PSA stabilization improved from 29% in Arm A to 45% in Arm C."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-008804","json":"https://secwatch.observer/filing/0001628280-22-008804.json","markdown":"https://secwatch.observer/filing/0001628280-22-008804.md","text":"https://secwatch.observer/filing/0001628280-22-008804.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022008804/0001628280-22-008804-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022008804/crdf-20220408.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T08:25:46.420914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}